Back to Search Start Over

Growth hormone treatment and health‐related quality of life in children and adolescents: A national, prospective, one‐year controlled study.

Authors :
Butler, Gary
Turlejski, Tymoteusz
Wales, Gillian
Bailey, Linda
Wright, Neil
Source :
Clinical Endocrinology; Aug2019, Vol. 91 Issue 2, p304-313, 10p, 3 Charts, 2 Graphs
Publication Year :
2019

Abstract

Background: Health‐related quality of life (HRQOL) may improve as an additional benefit of the growth hormone treatment (GHT) in children with short stature, but this effect has not been conclusively proven. Objectives: To explore the direct effect of GHT on HRQOL in children starting GHT due to isolated or multiple GH deficiency (IGHD), acquired GH deficiency (AGHD) and Turner syndrome (TS), in comparison with untreated short stature controls in 18 UK centres. Methods: We used recognized measures of HRQOL, the PedsQL, the Strengths and Difficulties Questionnaire and Youth Life Optimism Test scales to investigate the effect of GHT at 0, 6 and 12 months in children and adolescents 6‐16 years with IGHD (n = 73) and AGHD (n = 45), and 22 girls with TS. 49 children with non‐GHD short stature served as the controls. Results: Children rated their HRQOL better than their parents. Those with IGHD and TS rated their overall HRQOL lower than the controls at baseline, psychosocial scores significantly lower in IGHD. After 12 months, the control and TS groups scored higher than UK norms. Those with AGHD had lowest HRQOL scores at all time points, due to poorer physical functioning. The controls showed the greatest improvement in the strength and difficulties scale. All measures evaluated, whether from child, parent or teacher showed an equal improvement over the year of GHT with no discernible direct treatment effect, despite reduced numbers in some patient groups. Conclusions: Children with short stature resulting from GHD have lower functioning than controls but HRQOL appears to improve with GHT, most likely on account of greater attention and as a result of the retest phenomenon. We were not able to demonstrate an absolute and independent effect of GHT in itself. HRQOL should not be used as a primary measure, as in adults, to determine whether children should receive GHT. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03000664
Volume :
91
Issue :
2
Database :
Complementary Index
Journal :
Clinical Endocrinology
Publication Type :
Academic Journal
Accession number :
137489314
Full Text :
https://doi.org/10.1111/cen.14011